Open
Actively Recruiting
A Study of ADRX-0706 in Select Advanced Solid Tumors
About
Brief Summary
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
Primary Purpose
Study Type
Phase
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria:
- Phase 1a Dose Escalation: Subjects with histologically confirmed select advanced solid tumors, including urothelial carcinoma (UC), head and neck squamous cell carcinoma (HNSCC), breast cancer, cervical cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer. Subjects must have received at least one prior systemic regimen and have no other therapy available known to provide meaningful clinical benefit in the opinion of the investigator.
- Measurable disease according to RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate hematologic, liver, and renal function
Exclusion Criteria:
- Active and uncontrolled central nervous system metastases
- Significant cardiovascular disease
- History of another malignancy other than the one for which the subject is being treated on this study within 3 years
- Receipt of any anticancer or investigational therapy within 5 elimination half-lives or 14 days (whichever is less)
- Any P-gp inducers/inhibitors or strong CYP3A inhibitors received within 14 days prior to the first dose of study drug
- Receiving systemic antimicrobial treatment for active infection; routine antimicrobial prophylaxis is permitted
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
23-001142
Category
Other Cancer
Principal Investigator
Contact
Location
- UCLA Alhambra
- UCLA Beverly Hills
- UCLA Burbank
- UCLA Encino
- UCLA Irvine
- UCLA Pasadena
- UCLA Santa Monica
- UCLA Torrance
- UCLA Westwood